Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension

Christina A. Meadows, Michael G. Risbano, Li Zhang, Mark W. Geraci, Rubin M. Tuder, David H. Collier, Todd M. Bull

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Growth differentiation factor (GDF)-15 is a secreted member of the transforming growth factor-β cytokine superfamily. GDF-15 levels are elevated in the serum of patients with cardiovascular diseases. We hypothesized that GDF-15 levels would also be increased in the plasma and lung tissue of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Methods: GDF-15 levels were measured in plasma in subjects with SSc-PAH (n = 30) and compared with subjects with systemic sclerosis (SSc) without pulmonary arterial hypertension (PAH) (n = 24). Patients with idiopathic PAH (IPAH) (n = 44) and normal individuals (n = 13) served as control subjects. Immunohistochemistry and immunofluorescence assay identified GDF-15 protein in lung tissue from patients with SSc-PAH and IPAH. Results: Patients with SSc-PAH had significantly higher mean circulating levels of GDF-15 in plasma compared with patients with SSc without PAH (422.3 ± 369.5 pg/mL vs 108.1 ± 192.8 pg/mL, P = .004). GDF-15 levels correlated positively with estimated right ventricular systolic pressure on echocardiogram and plasma levels of the amino terminal propeptide form of brain natriuretic peptide. There was an inverse correlation between circulating GDF-15 and diffusing capacity of the lung for carbon monoxide (D LCO) and a positive correlation with the FVC to DLCO ratio on pulmonary function test. GDF-15 levels > 125 pg/mL were associated with reduced survival. GDF-15 protein expression was increased in lung tissue from patients with SSc-PAH. Conclusions: GDF-15 may be a useful biomarker in PAH associated with SSc. Its presence in lung tissue may suggest a role in the pathology of the disease.

Original languageEnglish (US)
Pages (from-to)994-1002
Number of pages9
JournalChest
Volume139
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Growth Differentiation Factor 15
Systemic Scleroderma
Pulmonary Hypertension
Lung
Lung Volume Measurements
Brain Natriuretic Peptide
Respiratory Function Tests
Transforming Growth Factors
Ventricular Pressure
Carbon Monoxide
Fluorescent Antibody Technique

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Meadows, C. A., Risbano, M. G., Zhang, L., Geraci, M. W., Tuder, R. M., Collier, D. H., & Bull, T. M. (2011). Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest, 139(5), 994-1002. https://doi.org/10.1378/chest.10-0302

Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. / Meadows, Christina A.; Risbano, Michael G.; Zhang, Li; Geraci, Mark W.; Tuder, Rubin M.; Collier, David H.; Bull, Todd M.

In: Chest, Vol. 139, No. 5, 01.05.2011, p. 994-1002.

Research output: Contribution to journalArticle

Meadows, CA, Risbano, MG, Zhang, L, Geraci, MW, Tuder, RM, Collier, DH & Bull, TM 2011, 'Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension', Chest, vol. 139, no. 5, pp. 994-1002. https://doi.org/10.1378/chest.10-0302
Meadows, Christina A. ; Risbano, Michael G. ; Zhang, Li ; Geraci, Mark W. ; Tuder, Rubin M. ; Collier, David H. ; Bull, Todd M. / Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. In: Chest. 2011 ; Vol. 139, No. 5. pp. 994-1002.
@article{37e22dc0890546298d69680474804f14,
title = "Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension",
abstract = "Background: Growth differentiation factor (GDF)-15 is a secreted member of the transforming growth factor-β cytokine superfamily. GDF-15 levels are elevated in the serum of patients with cardiovascular diseases. We hypothesized that GDF-15 levels would also be increased in the plasma and lung tissue of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Methods: GDF-15 levels were measured in plasma in subjects with SSc-PAH (n = 30) and compared with subjects with systemic sclerosis (SSc) without pulmonary arterial hypertension (PAH) (n = 24). Patients with idiopathic PAH (IPAH) (n = 44) and normal individuals (n = 13) served as control subjects. Immunohistochemistry and immunofluorescence assay identified GDF-15 protein in lung tissue from patients with SSc-PAH and IPAH. Results: Patients with SSc-PAH had significantly higher mean circulating levels of GDF-15 in plasma compared with patients with SSc without PAH (422.3 ± 369.5 pg/mL vs 108.1 ± 192.8 pg/mL, P = .004). GDF-15 levels correlated positively with estimated right ventricular systolic pressure on echocardiogram and plasma levels of the amino terminal propeptide form of brain natriuretic peptide. There was an inverse correlation between circulating GDF-15 and diffusing capacity of the lung for carbon monoxide (D LCO) and a positive correlation with the FVC to DLCO ratio on pulmonary function test. GDF-15 levels > 125 pg/mL were associated with reduced survival. GDF-15 protein expression was increased in lung tissue from patients with SSc-PAH. Conclusions: GDF-15 may be a useful biomarker in PAH associated with SSc. Its presence in lung tissue may suggest a role in the pathology of the disease.",
author = "Meadows, {Christina A.} and Risbano, {Michael G.} and Li Zhang and Geraci, {Mark W.} and Tuder, {Rubin M.} and Collier, {David H.} and Bull, {Todd M.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1378/chest.10-0302",
language = "English (US)",
volume = "139",
pages = "994--1002",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension

AU - Meadows, Christina A.

AU - Risbano, Michael G.

AU - Zhang, Li

AU - Geraci, Mark W.

AU - Tuder, Rubin M.

AU - Collier, David H.

AU - Bull, Todd M.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: Growth differentiation factor (GDF)-15 is a secreted member of the transforming growth factor-β cytokine superfamily. GDF-15 levels are elevated in the serum of patients with cardiovascular diseases. We hypothesized that GDF-15 levels would also be increased in the plasma and lung tissue of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Methods: GDF-15 levels were measured in plasma in subjects with SSc-PAH (n = 30) and compared with subjects with systemic sclerosis (SSc) without pulmonary arterial hypertension (PAH) (n = 24). Patients with idiopathic PAH (IPAH) (n = 44) and normal individuals (n = 13) served as control subjects. Immunohistochemistry and immunofluorescence assay identified GDF-15 protein in lung tissue from patients with SSc-PAH and IPAH. Results: Patients with SSc-PAH had significantly higher mean circulating levels of GDF-15 in plasma compared with patients with SSc without PAH (422.3 ± 369.5 pg/mL vs 108.1 ± 192.8 pg/mL, P = .004). GDF-15 levels correlated positively with estimated right ventricular systolic pressure on echocardiogram and plasma levels of the amino terminal propeptide form of brain natriuretic peptide. There was an inverse correlation between circulating GDF-15 and diffusing capacity of the lung for carbon monoxide (D LCO) and a positive correlation with the FVC to DLCO ratio on pulmonary function test. GDF-15 levels > 125 pg/mL were associated with reduced survival. GDF-15 protein expression was increased in lung tissue from patients with SSc-PAH. Conclusions: GDF-15 may be a useful biomarker in PAH associated with SSc. Its presence in lung tissue may suggest a role in the pathology of the disease.

AB - Background: Growth differentiation factor (GDF)-15 is a secreted member of the transforming growth factor-β cytokine superfamily. GDF-15 levels are elevated in the serum of patients with cardiovascular diseases. We hypothesized that GDF-15 levels would also be increased in the plasma and lung tissue of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Methods: GDF-15 levels were measured in plasma in subjects with SSc-PAH (n = 30) and compared with subjects with systemic sclerosis (SSc) without pulmonary arterial hypertension (PAH) (n = 24). Patients with idiopathic PAH (IPAH) (n = 44) and normal individuals (n = 13) served as control subjects. Immunohistochemistry and immunofluorescence assay identified GDF-15 protein in lung tissue from patients with SSc-PAH and IPAH. Results: Patients with SSc-PAH had significantly higher mean circulating levels of GDF-15 in plasma compared with patients with SSc without PAH (422.3 ± 369.5 pg/mL vs 108.1 ± 192.8 pg/mL, P = .004). GDF-15 levels correlated positively with estimated right ventricular systolic pressure on echocardiogram and plasma levels of the amino terminal propeptide form of brain natriuretic peptide. There was an inverse correlation between circulating GDF-15 and diffusing capacity of the lung for carbon monoxide (D LCO) and a positive correlation with the FVC to DLCO ratio on pulmonary function test. GDF-15 levels > 125 pg/mL were associated with reduced survival. GDF-15 protein expression was increased in lung tissue from patients with SSc-PAH. Conclusions: GDF-15 may be a useful biomarker in PAH associated with SSc. Its presence in lung tissue may suggest a role in the pathology of the disease.

UR - http://www.scopus.com/inward/record.url?scp=79955761934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955761934&partnerID=8YFLogxK

U2 - 10.1378/chest.10-0302

DO - 10.1378/chest.10-0302

M3 - Article

VL - 139

SP - 994

EP - 1002

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -